Literature DB >> 7208288

[Screening for phaeochromocytoma : in which hypertensive patients? A semiological study of 2585 patients, including 11 with phaeochromocytoma (author's transl)].

P F Plouin, P Degoulet, A Tugayé, M B Ducrocq, J Ménard.   

Abstract

In an attempt to find out whether phaeochromocytoma could be screened by questioning, the authors have recorded in a population of 2585 hypertensive patients the symptoms known to be most frequently associated with the tumour, i.e. headaches, palpitations and sweating attacks. Since 72.4% of the entire population reported one or another of these complaints, no single symptom could be taken as suggestive of phaeochromocytoma. However, only 6.5% of the patients reported all three symptoms and could therefore be considered as forming a subgroup likely to have the tumour. Patients in this subgroup differed from the others in the predominance of females (p less than 0.01), the higher frequency of anxiety (p less than 0.01) and above all, the higher incidence of phaeochromocytoma (5.9% as against 0.04%; p less than 0.01). The symptomatic triad (headaches, palpitations, sweating attacks) has a specificity of 93.8%, a sensitivity of 90.9% and an exclusion value of 99.9% for the diagnosis of phaeochromocytoma. Its presence in hypertensive patients justifies systematic assays of blood or urinary catecholamines. In its absence, the probability of phaeochromocytoma is inferior to 1 in 1 000.

Entities:  

Mesh:

Year:  1981        PMID: 7208288

Source DB:  PubMed          Journal:  Nouv Presse Med        ISSN: 0301-1518


  25 in total

1.  [An incidental finding of retrocaval extraadrenal pheochromocytoma].

Authors:  Katharina Maria Bretterbauer; Daniela Colleselli; Ahmed Magdy; Günter Janetschek; Michael Mitterberger
Journal:  Wien Med Wochenschr       Date:  2015-07-14

Review 2.  Pathophysiology of sympathoadrenal system.

Authors:  R Giorgino
Journal:  J Endocrinol Invest       Date:  1988-12       Impact factor: 4.256

3.  Pheochromocytoma.

Authors:  C Reuse; J L Vincent; C Matos; M de Rood; J Unger
Journal:  Intensive Care Med       Date:  1987       Impact factor: 17.440

Review 4.  Flushing in (neuro)endocrinology.

Authors:  Fady Hannah-Shmouni; Constantine A Stratakis; Christian A Koch
Journal:  Rev Endocr Metab Disord       Date:  2016-09       Impact factor: 6.514

5.  Mediastinal paraganglioma: time to panic?

Authors:  Constantinos A Parisinos; Fiona M Carnochan; Maria L Gregoriades; Hannah Monaghan; Dilip Patel; William S Walker
Journal:  BMJ Case Rep       Date:  2011-02-23

6.  Pheochromocytoma and paraganglioma.

Authors:  Vitaly Kantorovich; Karel Pacak
Journal:  Prog Brain Res       Date:  2010       Impact factor: 2.453

7.  Biochemical tests for pheochromocytoma: strategies in hypertensive patients.

Authors:  M J Young; C Dmuchowski; J W Wallis; G P Barnas; B Shapiro
Journal:  J Gen Intern Med       Date:  1989 Jul-Aug       Impact factor: 5.128

8.  Neurogenic hypertension associated with an excessively high excretion rate of catecholamine metabolites.

Authors:  C Funck-Brentano; J Y Pagny; J Menard
Journal:  Br Heart J       Date:  1987-05

Review 9.  [Pheochromocytoma - still a challenge].

Authors:  N Reisch; M K Walz; Z Erlic; H P H Neumann
Journal:  Internist (Berl)       Date:  2009-01       Impact factor: 0.743

10.  Malignant pheochromocytoma: clinical, biological, histologic and therapeutic data in a series of 20 patients with distant metastases.

Authors:  M Schlumberger; C Gicquel; J Lumbroso; F Tenenbaum; E Comoy; J Bosq; E Fonseca; P P Ghillani; B Aubert; J P Travagli
Journal:  J Endocrinol Invest       Date:  1992-10       Impact factor: 4.256

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.